Leerink Partners Reiterates Outperform Rating on Merck (MRK)
November 1, 2024 7:20 AM
Leerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating on Merck (NYSE: MRK).The analyst comments "Bottom Line: Gardasil remained ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
